Paper23093229
EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
Paliga A and 9 others. Br J Cancer, 2012. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Papers, record 23093229. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23093229
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anus Neoplasms | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Chemoradiotherapy | Major topic |
| ErbB Receptors | Major topic |
| Mutation | Major topic |
| Proto-Oncogene Proteins | Major topic |
| ras Proteins | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Exons | |
| Female | |
| Head and Neck Neoplasms | |
| Humans | |
| Immunohistochemistry | |
| Male | |
| Middle Aged | |
| Proto-Oncogene Proteins p21(ras) | |
| Squamous Cell Carcinoma of Head and Neck |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11597399 | EGFR and cancer prognosis. | Eur J Cancer | 2001 | https://conductscience.org/library/papers/11597399 | PubMed |
| 2 | 19519337 | Novel targeted radiosensitisers in cancer treatment. | Curr Drug Discov Technol | 2009 | https://conductscience.org/library/papers/19519337 | PubMed |
| 3 | 12499279 | Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. | Cancer Res | 2002 | https://conductscience.org/library/papers/12499279 | PubMed |
| 4 | 18337605 | EGFR antagonists in cancer treatment. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18337605 | PubMed |
| 5 | 19897418 | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. | Lancet Oncol | 2010 | https://conductscience.org/library/papers/19897418 | PubMed |
| 6 | 7968162 | ras mutations and expression in head and neck squamous cell carcinomas. | Laryngoscope | 1994 | https://conductscience.org/library/papers/7968162 | PubMed |
| 7 | 18495026 | High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. | BMC Cancer | 2008 | https://conductscience.org/library/papers/18495026 | PubMed |
| 8 | 21772841 | The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series. | J Oncol | 2011 | https://conductscience.org/library/papers/21772841 | PubMed |
| 9 | 22228639 | Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22228639 | PubMed |
| 10 | 19716155 | Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. | Hum Pathol | 2009 | https://conductscience.org/library/papers/19716155 | PubMed |
| 11 | 17089034 | Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? | Oncol Rep | 2006 | https://conductscience.org/library/papers/17089034 | PubMed |
| 12 | 15118073 | Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15118073 | PubMed |
| 13 | 2547513 | ras oncogenes in human cancer: a review. | Cancer Res | 1989 | https://conductscience.org/library/papers/2547513 | PubMed |
| 14 | 21450408 | Chemotherapy/chemoradiation in anal cancer: a systematic review. | Cancer Treat Rev | 2011 | https://conductscience.org/library/papers/21450408 | PubMed |
| 15 | 8210340 | Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. | Radiat Res | 1993 | https://conductscience.org/library/papers/8210340 | PubMed |
| 16 | 16467097 | Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16467097 | PubMed |
| 17 | 18946061 | K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18946061 | PubMed |
| 18 | 18519948 | Anal cancer: the end of the road for neoadjuvant chemoradiotherapy? | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18519948 | PubMed |
| 19 | 17538160 | Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17538160 | PubMed |
| 20 | 16648870 | Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. | Mod Pathol | 2006 | https://conductscience.org/library/papers/16648870 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40950666 | Clinical immunotherapeutic significance of RAS gene mutations in melanoma. | Transl Cancer Res | 2025 | https://conductscience.org/library/papers/40950666 | PubMed |
| 34790403 | Molecular characterization of squamous cell carcinoma of the anal canal. | J Gastrointest Oncol | 2021 | https://conductscience.org/library/papers/34790403 | PubMed |
| 34729104 | A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes. | J Cancer | 2021 | https://conductscience.org/library/papers/34729104 | PubMed |
| 34062753 | Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34062753 | PubMed |
| 33127962 | Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis. | Sci Rep | 2020 | https://conductscience.org/library/papers/33127962 | PubMed |
| 31851776 | VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). | Cancer Med | 2020 | https://conductscience.org/library/papers/31851776 | PubMed |
| 30651863 | Expression and role of EGFR, cyclin D1 and KRAS in laryngocarcinoma tissues. | Exp Ther Med | 2019 | https://conductscience.org/library/papers/30651863 | PubMed |
| 30128811 | Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy. | Med Oncol | 2018 | https://conductscience.org/library/papers/30128811 | PubMed |
| 29728940 | Systemic Therapies for Advanced Squamous Cell Anal Cancer. | Curr Oncol Rep | 2018 | https://conductscience.org/library/papers/29728940 | PubMed |
| 29137429 | Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. | Oncotarget | 2017 | https://conductscience.org/library/papers/29137429 | PubMed |
| 28261646 | Background and Current Treatment of Squamous Cell Carcinoma of the Anus. | Oncol Ther | 2016 | https://conductscience.org/library/papers/28261646 | PubMed |
| 28126304 | Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. | Int J Radiat Oncol Biol Phys | 2017 | https://conductscience.org/library/papers/28126304 | PubMed |
| 28068178 | Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28068178 | PubMed |
| 27937092 | Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/27937092 | PubMed |
| 27889034 | Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. | Surg Oncol Clin N Am | 2017 | https://conductscience.org/library/papers/27889034 | PubMed |
| 27886225 | No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). | Sci Rep | 2016 | https://conductscience.org/library/papers/27886225 | PubMed |
| 27219019 | Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. | Br J Cancer | 2016 | https://conductscience.org/library/papers/27219019 | PubMed |
| 26905274 | Advances in the Management of Anal Cancer. | Curr Oncol Rep | 2016 | https://conductscience.org/library/papers/26905274 | PubMed |
| 26498363 | Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. | Oncotarget | 2015 | https://conductscience.org/library/papers/26498363 | PubMed |
| 26487956 | Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. | J Gastrointest Oncol | 2015 | https://conductscience.org/library/papers/26487956 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ERBB3 | 2065 | PubTator's text mining | https://conductscience.org/library/genes/2065 | NCBI Gene |
| ERBB4 | 2066 | PubTator's text mining | https://conductscience.org/library/genes/2066 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23093229
GET https://conductscience.org/api/papers/v1/23093229/references?page=2